Abliva AB
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic … Read more
Abliva AB (ABLI) - Total Liabilities
Latest total liabilities as of December 2024: Skr11.86 Million SEK
Based on the latest financial reports, Abliva AB (ABLI) has total liabilities worth Skr11.86 Million SEK as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abliva AB - Total Liabilities Trend (2007–2024)
This chart illustrates how Abliva AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Abliva AB Competitors by Total Liabilities
The table below lists competitors of Abliva AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
E&P Financial Group Ltd
AU:EP1
|
Australia | AU$97.21 Million |
|
Chain Chon Industrial Co Ltd
TWO:5014
|
Taiwan | NT$6.21 Billion |
|
Red Robin Gourmet Burgers Inc
NASDAQ:RRGB
|
USA | $670.31 Million |
|
Playstudios Inc
NASDAQ:MYPS
|
USA | $60.23 Million |
|
Ecoplastic Corporation
KQ:038110
|
Korea | ₩1.21 Trillion |
|
EURO PRATIK SALES LIMITED
NSE:EUROPRATIK
|
India | ₹556.67 Million |
|
Thunderbird Entertainment Group Inc
OTCQX:THBRF
|
USA | $114.12 Million |
|
Mayfair Gold Corp
OTCQX:MFGCF
|
USA | $1.18 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Abliva AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abliva AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abliva AB (2007–2024)
The table below shows the annual total liabilities of Abliva AB from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr11.86 Million | -29.31% |
| 2023-12-31 | Skr16.78 Million | -14.13% |
| 2022-12-31 | Skr19.54 Million | +12.37% |
| 2021-12-31 | Skr17.39 Million | +68.83% |
| 2020-12-31 | Skr10.30 Million | -50.23% |
| 2019-12-31 | Skr20.70 Million | +13.12% |
| 2018-12-31 | Skr18.30 Million | +28.31% |
| 2017-12-31 | Skr14.26 Million | +14.87% |
| 2016-12-31 | Skr12.41 Million | -38.39% |
| 2015-12-31 | Skr20.15 Million | -14.00% |
| 2014-12-31 | Skr23.43 Million | +61.19% |
| 2013-12-31 | Skr14.53 Million | +71.74% |
| 2012-12-31 | Skr8.46 Million | +410.74% |
| 2011-12-31 | Skr1.66 Million | +69.52% |
| 2010-12-31 | Skr977.44K | -12.86% |
| 2009-12-31 | Skr1.12 Million | +75.07% |
| 2008-12-31 | Skr640.74K | -47.48% |
| 2007-12-31 | Skr1.22 Million | -- |